Centessa Pharmaceuticals plc financial data

Symbol
CNTA on Nasdaq
Location
3 Rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.06K % -16.7%
Debt-to-equity 42.6 % +14.7%
Return On Equity -67.7 % -29.9%
Return On Assets -47.5 % -24.9%
Operating Margin -1.43K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 134M shares +18.1%
Common Stock, Shares, Outstanding 134M shares +2.1%
Entity Public Float 622M USD +100%
Common Stock, Value, Issued 364K USD +1.96%
Weighted Average Number of Shares Outstanding, Basic 134M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 134M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 15M USD
General and Administrative Expense 50.2M USD +1.54%
Operating Income (Loss) -214M USD -32.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -239M USD -51.1%
Income Tax Expense (Benefit) 3.39M USD +15.4%
Net Income (Loss) Attributable to Parent -243M USD -50.5%
Earnings Per Share, Basic -1 USD/shares -24.2%
Earnings Per Share, Diluted -1 USD/shares -24.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 50.8M USD -87.1%
Other Assets, Current 2.76M USD +3.18%
Assets, Current 308M USD -45.9%
Deferred Income Tax Assets, Net 25M USD -7.51%
Property, Plant and Equipment, Net 894K USD +8.89%
Operating Lease, Right-of-Use Asset 10.3M USD -8.44%
Other Assets, Noncurrent 1.59M USD -28.8%
Assets 448M USD -26.5%
Accounts Payable, Current 8.68M USD +16.7%
Employee-related Liabilities, Current 5.95M USD -3.39%
Accrued Liabilities, Current 20.4M USD +7.78%
Liabilities, Current 29.1M USD +10.3%
Operating Lease, Liability, Noncurrent 7.76M USD -8.1%
Other Liabilities, Noncurrent 29K USD 0%
Liabilities 147M USD +32.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.6M USD +24.1%
Retained Earnings (Accumulated Deficit) -1.12B USD -27.7%
Stockholders' Equity Attributable to Parent 302M USD -39.6%
Liabilities and Equity 448M USD -26.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -57.2M USD -53.5%
Net Cash Provided by (Used in) Financing Activities 3.09M USD -70.6%
Net Cash Provided by (Used in) Investing Activities -222M USD -1427%
Common Stock, Shares Authorized 222M shares +20.6%
Common Stock, Shares, Issued 134M shares +2.1%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -278M USD -2734%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.8M USD -87.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.68M USD -33.5%
Deferred Tax Assets, Valuation Allowance 94.9M USD +29.6%
Deferred Tax Assets, Gross 124M USD +17.6%
Operating Lease, Liability 8.44M USD -6.4%
Depreciation 86K USD +132%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -242M USD -51.4%
Lessee, Operating Lease, Liability, to be Paid 12.8M USD -11.3%
Property, Plant and Equipment, Gross 1.91M USD +24.2%
Operating Lease, Liability, Current 684K USD +18.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.7M USD +1.98%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.67M USD +2.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 995K USD +129%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.36M USD -19.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.73M USD +2%
Deferred Tax Assets, Operating Loss Carryforwards 96.4M USD +24.5%
Unrecognized Tax Benefits 2.61M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.77M USD +2.02%
Operating Lease, Payments 408K USD +2%
Additional Paid in Capital 1.42B USD +3.25%
Depreciation, Depletion and Amortization 217K USD -9.58%
Deferred Tax Assets, Net of Valuation Allowance 29.3M USD -9.52%
Share-based Payment Arrangement, Expense 31.4M USD -3.96%
Interest Expense 10.1M USD +24.2%